Consistent Renal Benefits of Semaglutide in CKD and T2DM Patients With or Without SGLT2 Inhibitors Use. FLOW Trial

The FLOW trial showed that among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), once-weekly subcutaneous semaglutide was superior to placebo in improving renal and CV outcomes over a median follow-up of 3.4 years.
In this analysis, the benefits of semaglutide in improving renal outcomes were consistent in patients with/without baseline SGLT2i use

Benefits of Sotagliflozin Across Full Spectrum of EF

KEY POINTS:

Trials for those with heart failure with preserved ejection fraction have not previously demonstrated significant evidence of benefit to date
The use of the SGLT1/2 inhibitor, sotagliflozin, results in consistent, significant benefit in those with diabetes and reduced, midrange, and preserved ejection fraction

PURE Study Finds That Cardiovascular Disease Mortality Is Associated with the Glycemic Index of Foods in the Diet

A recent study by Dr. David J. A. Jenkins, published in the New England Journal Of Medicine, demonstrated that the glycemic index of the diet is directly associated with the risk of cardiovascular disease and death. This study was conducted in multiple countries and the results were similar across various economic and geographic regions. Continue reading →